Stock Track | Mesoblast Shares Soar 5.24% After Piper Sandler Boosts Target Price to $35

Stock Track

Oct 08, 2025

Shares of Mesoblast Ltd (MSB.AU) are soaring in Wednesday's intraday trading, climbing 5.24% following a bullish analyst update. The surge comes after Piper Sandler, a prominent investment bank, significantly raised its target price for the Australian biotechnology company.

Piper Sandler has increased its target price for Mesoblast from $24 to $35, representing a substantial 45.8% upward revision. This new target suggests considerable upside potential from the stock's current trading levels, sparking investor interest and driving the share price higher.

The raised target price often indicates an analyst's increased confidence in a company's future prospects. For Mesoblast, a company focused on developing and commercializing allogeneic cellular medicines, this positive outlook could be based on factors such as promising clinical trial results, potential regulatory approvals, or improved financial forecasts. Investors are likely interpreting this upgrade as a signal of Mesoblast's strengthening position in the competitive biotechnology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106846125"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106846125\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106846125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106846125","market":"sg","top_or_hot":-1,"title":"Stock Track | Mesoblast Shares Soar 5.24% After Piper Sandler Boosts Target Price to $35","media":"Stock Track","content":"<p>Shares of Mesoblast Ltd (MSB.AU) are soaring in Wednesday's intraday trading, climbing 5.24% following a bullish analyst update. The surge comes after Piper Sandler, a prominent investment bank, significantly raised its target price for the Australian biotechnology company.</p>\n\n<p>Piper Sandler has increased its target price for Mesoblast from $24 to $35, representing a substantial 45.8% upward revision. This new target suggests considerable upside potential from the stock's current trading levels, sparking investor interest and driving the share price higher.</p>\n\n<p>The raised target price often indicates an analyst's increased confidence in a company's future prospects. For Mesoblast, a company focused on developing and commercializing allogeneic cellular medicines, this positive outlook could be based on factors such as promising clinical trial results, potential regulatory approvals, or improved financial forecasts. Investors are likely interpreting this upgrade as a signal of Mesoblast's strengthening position in the competitive biotechnology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Shares Soar 5.24% After Piper Sandler Boosts Target Price to $35</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Shares Soar 5.24% After Piper Sandler Boosts Target Price to $35\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-08 07:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Mesoblast Ltd (MSB.AU) are soaring in Wednesday's intraday trading, climbing 5.24% following a bullish analyst update. The surge comes after Piper Sandler, a prominent investment bank, significantly raised its target price for the Australian biotechnology company.</p>\n\n<p>Piper Sandler has increased its target price for Mesoblast from $24 to $35, representing a substantial 45.8% upward revision. This new target suggests considerable upside potential from the stock's current trading levels, sparking investor interest and driving the share price higher.</p>\n\n<p>The raised target price often indicates an analyst's increased confidence in a company's future prospects. For Mesoblast, a company focused on developing and commercializing allogeneic cellular medicines, this positive outlook could be based on factors such as promising clinical trial results, potential regulatory approvals, or improved financial forecasts. Investors are likely interpreting this upgrade as a signal of Mesoblast's strengthening position in the competitive biotechnology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1106846125","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106846125","pubTimestamp":1759878255,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Mesoblast Ltd (MSB.AU) are soaring in Wednesday's intraday trading, climbing 5.24% following a bullish analyst update. The surge comes after Piper Sandler, a prominent investment bank,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"个股追踪|Piper Sandler将目标价上调至35美元后，Mesoblast股价飙升5.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"Shares of Mesoblast Ltd (MSB.AU) are soaring in Wednesday's intraday trading, climbing 5.24% following a bullish analyst update. The surge comes after Piper Sandler, a prominent investment bank, significantly raised its target price for the Australian biotechnology company.\nPiper Sandler has increased its target price for Mesoblast from $24 to $35, representing a substantial 45.8% upward revision. This new target suggests considerable upside potential from the stock's current trading levels, sparking investor interest and driving the share price higher.\nThe raised target price often indicates an analyst's increased confidence in a company's future prospects. For Mesoblast, a company focused on developing and commercializing allogeneic cellular medicines, this positive outlook could be based on factors such as promising clinical trial results, potential regulatory approvals, or improved financial forecasts. Investors are likely interpreting this upgrade as a signal of Mesoblast's strengthening position in the competitive biotechnology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}